A simplified and scalable synthesis of artesunate by unknown
ORIGINAL PAPER
A simplified and scalable synthesis of artesunate
Armin Presser1 • Andrea Feichtinger1 • Silke Buzzi1
Received: 21 September 2016 / Accepted: 25 October 2016 / Published online: 2 December 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract An efficient and economically viable approach
for the large-scale conversion of artemisinin into the anti-
malarial frontline drug artesunate was developed. This
advanced synthesis includes an NaBH4-induced reduction,
followed by an esterification with succinic anhydride under
basic conditions. The entire conversion follows the prin-
ciples of green chemistry, i.e., application of reusable
solvents.
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Introduction
Malaria, caused by parasitic protozoans of the Plasmodium
type, still remains a life-threatening disease with about
600,000 death cases each year, with many of them being
children under 5 years. The sesquiterpene endoperoxide
artemisinin (1) [1, 2], is the lead component of the so-
called artemisinin combination therapies (ACTs), which is
currently the most valuable weapon in the fight against this
disease. Several easily accessible artemisinin derivatives,
including dihydroartemisinin (DHA, 2) and artesunate (3),
exhibit potent antimalarial activity against drug-resistant
malaria strains [3–5]. In addition, they also show remark-
able activities against other parasites and various cancer
types [4, 6].
Artemisinin was discovered in the 1970s as a result of an
extensive screening of Chinese herbal extracts in the search
of new antimalarial agents [7]. Currently, the primary
method for the production of artemisinin is the isolation
from dried leaves of the plant Artemisia annua. Short-
comings of existing processes are poor yields and
environmental pollution [8]. Furthermore, the global sup-
ply of this life-saving drug exclusively from natural
sources remains highly limited. As a result, several novel
approaches for large-scale production of artemisinin have
been developed [9–13].
ACT medications rely not only on the procurement of
artemisinin, also the derivatives DHA (2, also known under
its INN identification artenimol) and artesunate (3) became
frontline drugs due to stronger activity and improved
bioavailability compared to the parent compound [1, 14].
The transformation of artemisinin into artesunate was
commonly realized by a two-step process involving the
reduction with NaBH4 [15–19], KBH4 [20, 21] or
diisobutylaluminium hydride (DIBAL) [22, 23], followed
by esterification using succinic anhydride [24, 25]. How-
ever, these syntheses described in the scientific literature
are not suitable for an industrial large-scale process
because they require very low temperature, highly expen-
sive or toxic reagents and solvents or provide only
moderate yields. Recently, some continuous flow protocols
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for the preparation of 2 and 3 were published [26–28].
Flow protocols have some technical advantages over batch
protocols. However, batch processing still dominates the
manufacturing of pharmaceuticals today.
On the basis of our earlier studies sponsored by
Medicines for Malaria Ventures (MMV) [29], we report
herein a facile and scalable synthetic route for the prepa-
ration of dihydroartemisinin (2) and artesunate (3) from 1
in high yields following the principles of green chemistry,
i.e., the minimization of waste, avoidance of toxic solvents,
and elimination of unnecessary steps.
Results and discussion
Our initial work started with the well-described reduction
of artemisinin with NaBH4 in methanol. THF or dioxane
were also used as solvents [30]; however, because of
ecological and economic reasons, the use of these solvents
was ruled out [31–33]. DIBAL in CH2Cl2 seems to be a
superior reagent for the conversion of artemisinin to DHA
[23], but it is more expensive and requires extremely low
temperature. The also known procedure with KBH4 in the
presence of a phase-transfer catalyst [20] shows some
inconsistencies and contains a rather hazy experimental
part.
After assessing diverse instructions from the literature,
we determined the most suitable conditions for the reduc-
tion of artemisinin: first, we identified the amount of
NaBH4 required for the complete transformation. As a
consequence of the competing methanol-induced solvoly-
sis, a certain excess of the reagent is definitely required. It
is known that the instability of NaBH4 in MeOH can be
overcome by the addition of a base [34], but the extreme
vulnerability of DHA towards small amounts of strong
bases [21] excludes this approach. Apparently, the appli-
cation of a lower reaction temperature leads to a slower
decomposition of NaBH4 by MeOH [21]. As a conse-
quence, the reaction time has to be kept short, and the
reaction temperature kept as low as possible. Due to the
decrease of the reaction temperature, the excess of NaBH4
could be considerably reduced as compared to the pub-
lished instructions. However, a contamination of the
reagent with traces of strong bases will also have a negative
impact on the yield.
The best results were achieved when 2.5 equiv. of
NaBH4 were added to a suspension of approx. 0.6 M
artemisinin in MeOH at 0–5 C over 30 min and a total
reaction time of 1 h (Scheme 1). Two different types of
NaBH4, powder and granulate, were tested. Even though
the yields are identical, the use of granulated material is
preferred because the production of toxic dust during
handling is minimized. Subsequently, the work-up
conditions were optimized. After destroying the excess
of NaBH4 with acetic or hydrochloric acid, DHA is
usually precipitated by the addition of water. Through
this procedure, DHA could be obtained in satisfactory
yields (79–89%) as published previously [16, 19, 21]. In
an alternative strategy, the yield of DHA could be fur-
ther enhanced by neutralization with 30% acetic acid/
MeOH at 0–5 C, concentration, and multiple extraction
of the white residue using Et-OAc. Evaporation under
reduced pressure provided 2 as a white crystalline
powder in 98% yield, which can be used in the next step
without further purification. To reduce the large con-
sumption of Et-OAc, the solvent was distilled and
reused.
Bulk solid DHA results solely as b-epimer of the lactol
hemiacetal [35]. Addition of CDCl3 provides a solution
consisting exclusively of 2b, which equilibrates gradually
to a 1:1 mixture of 2a and 2b. The epimerization is clearly
indicated by arising signals at 5.39 ppm (H-12a) and
4.75 ppm (H-10a) in the 1H NMR spectrum (see Fig. 1).
The equilibrium ratio is depending on the solvent [36]: in
CH3CN/H2O which we used for HPLC analysis, the rela-
tion of 2a and 2b is 3:1.
Acylation of DHA (2) to artesunate (3) was first realized
with succinic anhydride in the presence of pyridine as a
base/solvent [24]. The use of catalytic DMAP was also
reported [37] with a yield of 65%. Aside from Chinese
publications, there exist only marginal instructions [25] for
the preparation of 3 so far. Also, a patent specification with
Et3N as base in acetone, THF, or dioxane promising yields
up to 97% [38] was not reproducible [36]. Pharmaceuti-
cally approved artesunate is an a-linked dihydroartemisinin
hemisuccinate. It was reported that acylation of DHA in
alkaline media led almost exclusively to a-configured
derivatives [35, 39]. An obvious reason may be the crow-
ded environment of the axial hydroxyl in the b-epimer or
the higher stability and thermodynamically favored con-
formation of 2a. The classical esterification method using
acid chlorides or anhydrides in pyridine (Einhorn method)
requires anhydrous conditions. In our first attempt, we
replaced the originally used pyridine by Et3N and chose Et-
OAc as a reusable and ecologically more acceptable sol-
vent. A supplemental addition of DMAP as well as the
usage of anhydrous solvents appeared to be negligible. To
further improve the reaction conditions, we investigated the
stoichiometric ratio of the reagents. As shown in Table 1,
the esterification occurred almost quantitatively with a 1.4-
fold excess of succinic anhydride using 0.6 equiv. of Et3N.
The reaction can take place at RT or even higher temper-
ature (up to 50 C) without any difference in yield.
Unfortunately, the recycling of Et-OAc by distillation
leaves a water content up to 8.5% [40] which negatively
affects the yield when reused solvent was applied. This dif-
ficulty was overcome by changing the reaction medium to
64 A. Presser et al.
123
isopropyl acetate. Because of the lower moisture content
(1.5% determined via Carl Fischer titration), even after
recycling of the solvent, artesunate was obtained in the same
excellent yields. 1H NMR spectroscopic analyses confirmed
that exclusively a-artesunate was formed; the large trans-
diaxial coupling of H-10 at 5.67 ppm (J10,9 = 9.7 Hz) pin-
points the requested configuration at C-10.
Conclusion
In summary, we report on the development of an advanced
synthetic route for the conversion of the natural product
artemisinin into semisynthetic artesunate by NaBH4-in-
duced reduction and subsequent esterification under basic
conditions as pivotal steps. Using our synthetic approach,
feasibility and scalability of the synthesis can be dramati-
cally improved while the overall yield remains among the
best so far documented. This procedure should favorably
complement the existing routes and may represent an
additional entry to the production of artesunate at low
costs.
Experimental
Melting points were obtained on a digital melting point
apparatus (Electrothermal IA 9200). The NMR spectra
were measured on a Varian Unity Inova 400 instrument (at
298 K) using 5-mm tubes. Chemical shifts were given in
parts per million (ppm); the tetramethylsilane (TMS) res-
onance (0.00 ppm) was used as internal standard. Coupling
constants (J) were reported in Hertz (Hz). 1H and 13C
resonances were assigned using 1H, 1H and 1H, 13C cor-
relation spectra. 1H and 13C resonances are numbered as
given in the formulae. The signals marked with an asterisk
are interchangeable. The IR spectra were recorded on an
ALPHA FT-IR-spectrometer (Bruker). Optical rotation was
determined on a P-2000 polarimeter (Jasco). The water
content of the solvents was quantified via Carl Fischer
titration on a TitroLine 7500 KF (SI Analytics). HPLC
separations were performed on a Merck Hitachi HPLC
apparatus D6000A consisting of a pump L6200 and UV–
Vis-detector L4250. Diastereomer separation was achieved
using a LiChrospher 100 RP–18 (5 lm, 125 9 3 mm,
Merck) HPLC column, operated at 30 C. Each 10-min
chromatographic run was carried out at a flow rate of
0.5 cm3/min with an isocratic mobile phase consisting of
acetonitrile (20%) and Millipore water (80%). Runtime
was 10 min and detection wavelength was 224 nm. The
purity of artesunate was checked by HPLC analysis per-
formed on an Agilent 1200 series equipped with an
autosampler, a quaternary pump system and a photodiode
array detector. An Agilent Zorbax SP-C18 column (particle
size 3.5 lm; 2.1 9 150 mm with guard cartridge) was used
Scheme 1
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Fig. 1 1H NMR of DHA (2): immediately after dissolution (a) and after 12 h (b)
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at a flow rate of 0.30 cm3/min. The chromatographic
method was performed with a gradient of acetonitrile
(A) in Millipore water (B), both with each 0.1% HCOOH,
from 10 to 90% A in B within 20 min, then to 100% A
within 5 min followed by returning to starting conditions
within 1 min and re-equilibration for 8 min. 10 mm3 of
sample was injected and detection was done at 220 nm.
Materials: TLC was carried out on Merck TLC plates
(silica gel 60 F254 0.2 mm, 200 9 200 mm). TLCs were
visualized by spraying with cerium(IV) sulfate/ammonium
molybdate and subsequent heating with a heat gun. The
solvents were concentrated by rotary evaporation below
50 C. Purity and homogeneity of compounds were




Artemisinin (10.0 g, 35.4 mmol) was suspended in 60 cm3
MeOH and cooled in an ice bath to 0–5 C. To the sus-
pension, 3.35 g of NaBH4 (88.5 mmol) was added in small
portions over a period of 30 min. After the addition of
NaBH4 was complete, the reaction was allowed to reach
ambient temperature and was stirred vigorously under Ar
until the TLC showed complete consumption of 1
(*30 min). The mixture was neutralized (pH 5–6) with
30% AcOH/MeOH, concentrated under reduced pressure
and finally lyophilized. The white residue was extracted
with Et-OAc several times. The combined Et-OAc extracts
were filtered and evaporated to dryness to give 9.87 g
(98%) DHA as a white crystalline powder, which can be
used in the next step without further purification. Rf = 0.46
(CH2Cl2:MeOH = 20:1), m.p.: 150–151 C (Ref. [41],
152–153 C). The spectroscopic data were found to be





A solution of 4.93 g succinic anhydride (49.2 mmol) in
30 cm3 isopropyl acetate was treated under Ar with
2.94 cm3 Et3N (21.1 mmol). To this solution, 10.0 g of 2
(35.2 mmol) was successively added over a period of
30 min and the mixture was stirred at ambient temperature
for 4 h. Then, it was quenched with H2O and H2SO4 (2 N)
until pH 5 was reached and stirred for a few minutes to
achieve phase separation. The aqueous phase was extracted
thoroughly with isopropyl acetate and the combined
organic layers were concentrated under reduced pressure
providing almost pure a-artesunate (impurities \1%) as
fine white needles. Yield 12.7 g (94%).
A batch size over 50 g DHA requires a modified work-
up: After quenching with a small amount of H2O and
neutralization with H2SO4 (2 N), the mixture was diluted
with isopropyl acetate and heated to 50 C to dissolve
precipitated 3. The organic layer was washed with warmish
H2O and concentrated under reduced pressure providing a-
artesunate as described above. Rf = 0.27 (CH:Et-
OAc = 1:1), m.p.: 131–133 C (MeOH:H2O = 1:2) (Ref.
[39], 135 C). The spectroscopic data were found to be
identical to the ones described in Refs. [39, 44]. Although
the crystal structure of 3 is already known [39], to the best
of our knowledge, a complete assignment of the NMR
signals has never been published: 1H NMR (400 MHz,
DMSO-d6): d = 5.67 (d, J = 9.7 Hz, 1H, H-10), 5.56 (s,
1H, H-12), 2.63–2.58 (m, 2H, H-180, H-190), 2.53–2.48 (m,
2H, H-1800, H-1900), 2.35–2.23 (m, 1H, H-9), 2.18 (td,
J = 13.9, 3.9 Hz, 1H, H-40), 2.00 (dt, J = 13.9, 3.9 Hz,
1H, H-400), 1.81 (dq, J = 10.3, 3.5 Hz, 1H, H-50),




Entry Succ. anhydr./equiv Et3N/equiv Temp./C Yield/%a
1 2.0 1.1 25 86
2 1.5 1.1 25 81
3 1.5 1.1 50 80
4 1.2 1.1 25 58
5 1.5 0.8 25 85
6 1.3 0.8 25 83
7 1.3 0.6 25 89
8 1.3 0.6 40 88
9 1.4 0.6 25 94
Reaction conditions: dihydroartemisinin (2, 35.2 mmol), succinic anhydride and Et3N as stated above,
30 cm3 solvent; the reactions were monitored by TLC until the apparent consumption of the limiting
substrate
a Isolated yield
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1.67–1.61 (m, 1H, H-80), 1.64–1.57 (m, 1H, H-70),
1.58–1.51 (m, 1H, H-8a), 1.48–1.41 (m, 1H, H-800),
1.47–1.37 (m, 1H, H-6), 1.36–1.27 (m, 1H, H-500), 1.29
(s, 3H, H-13), 1.19 (dd, J = 11.3, 6.4 Hz, 1H, H-5a),
1.02–0.88 (m, 1H, H-700), 0.89 (d, J = 6.4 Hz, 3H, H-14),
0.77 (d, J = 7.1 Hz, 3H, H-15) ppm.; 13C NMR
(100 MHz, DMSO-d6): d = 173.7 (C-20), 171.5 (C-17),
104.0 (C-3), 92.2 (C-10), 91.1 (C-12), 80.3 (C-12a), 51.6
(C-5a), 45.0 (C-8a), 36.4 (C-4, C-6), 34.2 (C-7), 32.1 (C-9),
29.2* (C-18), 28.9* (C-19), 26.0 (C-13), 24.7 (C-5), 21.5
(C-8), 20.5 (C-14), 12.2 (C-15) ppm.
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